{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:11:53Z","timestamp":1785813113097,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.diabet.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T03:32:25Z","timestamp":1519097545000},"page":"508-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk"],"prefix":"10.1016","volume":"44","author":[{"given":"W.","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Siniawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huer\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Val\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2018.02.005_bib0205","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.02.005_bib0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.02.005_bib0215","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14779072.2016.1189327","article-title":"Cholesteryl ester transfer protein inhibitors: challenges and perspectives","volume":"14","author":"Filippatos","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.diabet.2018.02.005_bib0220","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2018.02.005_bib0225","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0230","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0235","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0240","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0245","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","article-title":"High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus","volume":"119","author":"Drew","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.02.005_bib0250","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00125-014-3162-7","article-title":"Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice","volume":"57","author":"Stenkula","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2018.02.005_bib0255","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/db07-0056","article-title":"Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction","volume":"56","author":"Hao","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.02.005_bib0260","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2018.02.005_bib0265","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.diabet.2018.02.005_bib0270","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabet.2018.02.005_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2012.06.001","article-title":"Statins are diabetogenic \u2013 myth or reality?","volume":"13","author":"Sattar","year":"2012","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.diabet.2018.02.005_bib0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","article-title":"Are statins diabetogenic?","volume":"26","author":"Sampson","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0290","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/dom.12255","article-title":"Postprandial effects of long-term niacin\/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome","volume":"16","author":"Aye","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabet.2018.02.005_bib0295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.atherosclerosis.2015.08.015","article-title":"Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease","volume":"242","author":"Koopal","year":"2015","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.diabet.2018.02.005_bib0300","doi-asserted-by":"crossref","first-page":"e27208","DOI":"10.1371\/journal.pone.0027208","article-title":"Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study","volume":"6","author":"L\u00f3pez-R\u00edos","year":"2011","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.diabet.2018.02.005_bib0305","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.diabet.2018.02.005_bib0310","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/db14-1710","article-title":"Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes","volume":"64","author":"Fall","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.02.005_bib0315","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fphar.2015.00258","article-title":"HDL and glucose metabolism: current evidence and therapeutic potential","volume":"6","author":"Siebel","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0320","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cvr\/cvu143","article-title":"High-density lipoprotein, beta cells, and diabetes","volume":"103","author":"von Eckardstein","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.02.005_bib0325","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/ATVBAHA.110.207373","article-title":"Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion","volume":"30","author":"Fryirs","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0330","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1074\/jbc.M111.268185","article-title":"Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells","volume":"287","author":"Cantrell Stanford","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2018.02.005_bib0335","first-page":"659","article-title":"Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function","volume":"61","author":"Kruit","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2018.02.005_bib0340","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1172\/JCI41280","article-title":"An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells","volume":"120","author":"Sturek","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2018.02.005_bib0345","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1161\/ATVBAHA.114.304131","article-title":"Apolipoprotein A-I increases insulin secretion and production from pancreatic beta-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism","volume":"34","author":"Cochran","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0350","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/me.2008-0448","article-title":"Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta-cells","volume":"23","author":"Petremand","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.atherosclerosis.2014.01.028","article-title":"Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters","volume":"233","author":"Briand","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2018.02.005_bib0360","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1752-8062.2011.00344.x","article-title":"CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice","volume":"4","author":"Briand","year":"2011","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.diabet.2018.02.005_bib0365","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","article-title":"Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"124","author":"Barter","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.02.005_bib0370","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0375","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.005_bib0380","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.005_bib0385","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabet.2018.02.005_bib0390","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1051\/medsci\/2010264385","article-title":"Cholesterol metabolism and beta-cell function","volume":"26","author":"Langhi","year":"2010","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.diabet.2018.02.005_bib0395","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/en.2009-0252","article-title":"Low and high density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells","volume":"150","author":"Rutti","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2018.02.005_bib0400","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618300454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618300454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T13:42:41Z","timestamp":1541166161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363618300454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1262363618300454"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2018.02.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}